Sanofi stock climbs as MenQuadfi approval and cuts reshape the story
Published on 08/18/2026 at 14:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi (FR0000127771) stock is trading at $44.40 on August 18, 2026, with a market value of $106.39 billion and a 1.56 percent daily gain in the latest US quote snapshot. The same session also shows the Paris listing at EUR76.66, keeping the French drugmaker in a clear large-cap range.
MenQuadfi adds fresh support
An EU approval expanded MenQuadfi to infants from six weeks of age, giving Sanofi a new vaccines catalyst with visible commercial relevance. The coverage tied that move to a mid-August share price of EUR76.66 and a one-day return of 1.51 percent.
That matters because the same market snapshot points to a stock that is still down 6.88 percent year to date in Paris despite the approval, so the announcement supports the case for a better operating mix rather than a full valuation reset. The number that stands out is the gap between EUR76.66 and an estimated fair value of EUR96.70 in the same analysis.
Q2 numbers set the frame
Sanofi's latest quarter in the available coverage was Q2 2026, with revenue of $12.3 billion and earnings of $343 million. Normalized GAAP EPS came in at $1.20 versus consensus of $1.14, a 6 cent beat that shows profitability held up even with disciplined top-line growth.
Another August 18, 2026 market snapshot shows the US ADR at $44.41 after a $0.69 rise, while the same source highlights a consensus rating of Hold and a 12-month target of $49.50. For investors, that places the shares in the middle of a narrow analyst range rather than at a clear momentum breakout.
Blueprint reshaping
A separate August 17, 2026 report says Sanofi is cutting 229 employees tied to legacy Blueprint Medicines operations in Massachusetts and closing offices in Cambridge. The move adds a cost and integration angle to the story alongside the vaccine approval.
That combination matters because it links a product win with portfolio cleanup: MenQuadfi can help the top line, while the Blueprint restructuring should simplify the cost base over time. The two developments point in the same direction, but through different parts of the income statement.
MenQuadfi focus
MenQuadfi is Sanofi's meningococcal vaccine, and the newly widened EU use in infants from six weeks gives it a broader addressable market in a key region. Vaccines remain one of Sanofi's most visible franchises, so the approval is relevant beyond a single regulatory headline.
Share level
As of August 18, 2026, Sanofi's US-listed shares were at $44.40 and the market cap stood at $106.39 billion. The Paris listing was quoted at EUR76.66 in the latest same-day snapshot.
Fact box
Company: Sanofi
ISIN: FR0000127771
Ticker: SNY
Exchange: Nasdaq ADR / Euronext Paris
Price (as of August 18, 2026, 4:00 p.m. ET): $44.40 USD
Market cap: $106.39 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: CAC 40
